Press "Enter" to skip to content

Pfizer’s cut-price version of Avastin wins EU panel greenlight

Pfizer’s Zirabev is the second cancer biosimilar from the drugmaker to receive a positive opinion from the European advisory panel this year.

Original source: https://health.economictimes.indiatimes.com/news/pharma/pfizers-cut-price-version-of-avastin-wins-eu-panel-greenlight/67103499?utm_source=RSS&utm_medium=ETRSS

Also Read:   Shilpa Medicare gets EIR from USFDA for Raichur facility